SCHEMBL996482

SCHEMBL996482

O=c1[nH]cnc2c1CNCC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 4/20 0.37
PARP1 P09874 3/20 0.37
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
GABRA1 P14867 1/20 0.35
CYP2C19 P33261 1/20 0.35
GABRB2 P47870 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CHEK1 O14757 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
TNKS2 Q9H2K2 2/20 0.34
TNKS O95271 1/20 0.34
GMNN O75496 1/20 0.34
BLM P54132 1/20 0.34
GAA P10253 1/20 0.34
EGFR P00533 1/20 0.33
HPGD P15428 1/20 0.32
PARP2 Q9UGN5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1018236 0.98 GMNN (0.37) SRCPARP1ALDH1A1KMT2AMEN1
SCHEMBL30213528 0.89 NPSR1 (0.36) SRCPARP1ALDH1A1KMT2ANPSR1
SCHEMBL4872148 0.85 KMT2A (0.39) SRCPARP1ALDH1A1KMT2AMEN1
SCHEMBL15864203 0.82 SRC (0.40) SRCPARP1ALDH1A1KMT2ANPSR1
SCHEMBL1073971 0.78
SCHEMBL3542410 0.75 NPSR1 (0.49) SRCALDH1A1KMT2ANPSR1CHEK1
SCHEMBL2624085 0.75 TSHR (0.49) SRCPARP1ALDH1A1KMT2ANPSR1
SCHEMBL13911357 0.73 GAA (0.50) SRCPARP1ALDH1A1KMT2ANPSR1
SCHEMBL12349970 0.73 GAA (0.50) SRCPARP1ALDH1A1KMT2ANPSR1
SCHEMBL399938 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP claimed
CN-115427409-B Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists 拉夸里亚创药株式会社 2025-02-25 CN claimed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US claimed
CN-115776890-A TRPV4 inhibitors as therapeutic agents for eye diseases 拉夸里亚创药株式会社 2023-03-10 CN claimed
EP-4142874-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RaQualia Pharma Inc. (JP) 2023-03-08 EP claimed
CN-114957246-A 5,6,7, 8-tetrahydropyrido [4,3-d ] pyrimidin-4 (3H) -one derivatives and application thereof 苏州恩华生物医药科技有限公司 2022-08-30 CN claimed
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
US-20260092076-A1 NOVEL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2026-04-02 US disclosed
EP-4695243-A1 NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2026-02-18 EP disclosed
CN-114957246-B 5,6,7, 8-Tetrahydropyrido [4,3-d ] pyrimidin-4 (3H) -one derivatives and uses thereof 苏州恩华生物医药科技有限公司 2025-11-11 CN disclosed
CN-115427409-B Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists 拉夸里亚创药株式会社 2025-02-25 CN disclosed
WO-2024213552-A1 NLRP3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-10-17 WO disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20080139586-A1 Mitotic Kinesin Inhibitors MERCK SHARP & DOHME CORP. 2008-06-12 US disclosed
US-20080139586-A1 Mitotic Kinesin Inhibitors MERCK SHARP & DOHME CORP. 2008-06-12 US disclosed
EP-1885369-A2 FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF Renovis, Inc. (US) 2008-02-13 EP disclosed
US-20060258689-A1 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans EVOTEC SE (DE) 2006-11-16 US disclosed
WO-2006119504-A2 FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF RENOVIS, INC. (US) 2006-11-09 WO disclosed
WO-2006119504-A2 FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF RENOVIS, INC. (US) 2006-11-09 WO disclosed
WO-2004014909-A1 FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258689-A1 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans BDNF, OPRL1, GRIN2D SRC 4251/4885PARP1 692/4885ALDH1A1 1525/4885
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 SRC 3184/4885PARP1 2542/4885ALDH1A1 1663/4885
US-20260092076-A1 NOVEL COMPOUNDS NOD1, NLRP3, ARRB1 SRC 2211/4885PARP1 351/4885ALDH1A1 622/4885
US-20080139586-A1 Mitotic Kinesin Inhibitors KIF5B, KIF2C, KIFC1 SRC 2156/4885PARP1 853/4885ALDH1A1 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.